These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 16353949)
21. Impact of psychostimulants on vesicular monoamine transporter function. Fleckenstein AE; Hanson GR Eur J Pharmacol; 2003 Oct; 479(1-3):283-9. PubMed ID: 14612158 [TBL] [Abstract][Full Text] [Related]
22. Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation. Seger D Clin Toxicol (Phila); 2010 Aug; 48(7):695-708. PubMed ID: 20849328 [TBL] [Abstract][Full Text] [Related]
23. The dopamine transporter: a vigilant border control for psychostimulant action. Williams JM; Galli A Handb Exp Pharmacol; 2006; (175):215-32. PubMed ID: 16722238 [TBL] [Abstract][Full Text] [Related]
24. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Buck KJ; Amara SG Mol Pharmacol; 1995 Dec; 48(6):1030-7. PubMed ID: 8848002 [TBL] [Abstract][Full Text] [Related]
25. Neurotransmitter transporters in schistosomes: structure, function and prospects for drug discovery. Ribeiro P; Patocka N Parasitol Int; 2013 Dec; 62(6):629-38. PubMed ID: 23800409 [TBL] [Abstract][Full Text] [Related]
30. A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Robertson SD; Matthies HJ; Galli A Mol Neurobiol; 2009 Apr; 39(2):73-80. PubMed ID: 19199083 [TBL] [Abstract][Full Text] [Related]
31. Proteins interacting with monoamine transporters: current state and future challenges. Sager JJ; Torres GE Biochemistry; 2011 Aug; 50(34):7295-310. PubMed ID: 21797260 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of monoamine transporter substrates. Rothman RB; Baumann MH Curr Top Med Chem; 2006; 6(17):1845-59. PubMed ID: 17017961 [TBL] [Abstract][Full Text] [Related]
33. Pharmacology of Drugs Used as Stimulants. Docherty JR; Alsufyani HA J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S53-S69. PubMed ID: 34396557 [TBL] [Abstract][Full Text] [Related]
34. Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Howell LL; Negus SS Adv Pharmacol; 2014; 69():129-76. PubMed ID: 24484977 [TBL] [Abstract][Full Text] [Related]
35. Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex. Rollema H; Wilson GG; Lee TC; Folgering JH; Flik G Neurochem Int; 2011 Jan; 58(1):78-84. PubMed ID: 21056607 [TBL] [Abstract][Full Text] [Related]
36. New insights into the mechanism of action of amphetamines. Fleckenstein AE; Volz TJ; Riddle EL; Gibb JW; Hanson GR Annu Rev Pharmacol Toxicol; 2007; 47():681-98. PubMed ID: 17209801 [TBL] [Abstract][Full Text] [Related]
37. Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies. Bottalico B; Larsson I; Brodszki J; Hernandez-Andrade E; Casslén B; Marsál K; Hansson SR Placenta; 2004 Jul; 25(6):518-29. PubMed ID: 15135235 [TBL] [Abstract][Full Text] [Related]
38. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Daws LC Pharmacol Ther; 2009 Jan; 121(1):89-99. PubMed ID: 19022290 [TBL] [Abstract][Full Text] [Related]